Skip to main content
. 2023 Sep 7;10(6):e200163. doi: 10.1212/NXI.0000000000200163

Figure 1. Longitudinal Dynamics of Antibodies Against SARS-CoV-2 Receptor-Binding Domain According to the Type of Treatment.

Figure 1

(T1) before vaccination; (T2) 1 month after the first dose; (T3) 1 month after the second dose, (T4) 6 months after the first dose, and (T6) 12 months after the first dose. Receptor-binding domain antibody levels are expressed as mean (SD) of the median fluorescence intensity ratio. Patients treated with anti-CD20 or fingolimod had significantly lower levels of receptor-binding domain antibodies than those treated with other therapies across different time points (compared by general lineal model adjusted by age). Other therapy includes untreated patients and those treated with other therapy than anti-CD20 and fingolimod (as detailed in Table 1). The number of patients with receptor-binding domain antibodies before vaccination (at T1) included 61 in the group treated with other therapies (blue), 8 in the group anti-CD20 (red), and 5 in the group fingolimod (light green).